Gracell Biotechnologies Presents Clinical Data for FasTCAR-T GC012F for High Risk, Newly Diagnosed Multiple Myeloma Demonstrating 100% Overall Response Rate
PR Newswire
December 11, 2022 β 07:15 CST
UNLOCK DATA Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech